Log in to search using one of your social media accounts:

 

Abemaciclib: First-Line CDK4/6 Inhibitor for Breast Cancer Abemaciclib: First-Line CDK4/6 Inhibitor for Breast Cancer
Abemaciclib, the third CDK4/6 inhibitor, in combination with endocrine therapy shows significant benefit for the first-line treatment of HR+ HER2- advanced breast cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Abemaciclib initial therapy improves outcome in endocrine-sensitive advanced breast cancer
(European Society for Medical Oncology) The results of the MONARCH 3 trial, presented at the ESMO 2017 Congress in Madrid (1), showed that adding the cyclin-dependent kinase (CDK) 4/6 inhibitor abemaciclib to endocrine therapy improved progression-free survival compared to endocrine therapy alone in the total study population. While most women had substantial benefit from the addition of abemaciclib as initial treatment, around one-third of women may not need a CDK 4/6 inhibitor as initial treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 9, 2017 Category: Cancer & Oncology Source Type: news

Extended AI Use Linked to CV Events and Bone Fractures Extended AI Use Linked to CV Events and Bone Fractures
There is growing interest in extending the use of adjuvant endocrine therapy in breast cancer, but the benefit vs risk for toxicity is not yet defined.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 29, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer
This video highlights trials studying the long-term impact of adjuvant tamoxifen and aromatase inhibitors for the treatment of patients with postmenopausal breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - August 25, 2017 Category: Cancer & Oncology Authors: Prudence A. Francis, MD Tags: Videos Breast Cancer Source Type: news

Using Molecular Tools to Guide Breast Cancer Treatment
This video examines the use of molecular diagnostics for guiding adjuvant endocrine therapy in patients with breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - August 22, 2017 Category: Cancer & Oncology Authors: Philippe L. Bedard, MD Tags: Breast Cancer Videos Breast Cancer Source Type: news

Papers of note in Science Translational Medicine 9 (402)
This week’s articles describe a way to prevent a major side effect of chemotherapy, paths of endocrine therapy resistance in breast cancer, and a new treatment for type 1 diabetes. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - August 15, 2017 Category: Science Authors: Ferrarelli, L. K. Tags: STKE Editors ' Choice Source Type: news

AstraZeneca ’s faslodex receives EU approval for advanced breast cancer treatment
The European Commission (EC) has approved AstraZeneca ’s faslodex (fulvestrant) for the treatment of oestrogen-receptor positive, locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 27, 2017 Category: Pharmaceuticals Source Type: news

' Right' Endocrine Therapy a Question in Youngest BC Patients'Right' Endocrine Therapy a Question in Youngest BC Patients
An analysis of the SOFT and TEXT trial results throws some light on the question of which endocrine therapy is best in young patients with breast cancer.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 25, 2017 Category: Consumer Health News Tags: Hematology-Oncology Viewpoint Source Type: news

T-DM1 in Early HER2+/HR+ Breast Cancer Offers Good Response Rates
T-DM1 administered for 12 weeks with or without endocrine therapy yields good rates of pathologic complete response in women with HER2-positive/hormone receptor –positive breast cancer, according to a new randomized trial. (Source: CancerNetwork)
Source: CancerNetwork - July 14, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Source Type: news

' Ultralow-Risk' Breast Cancers Can Skip Endocrine Therapy'Ultralow-Risk' Breast Cancers Can Skip Endocrine Therapy
' Ultralow-risk breast cancer'is a not commonly used term, but a new study suggests that patients with such cancers could receive less treatment.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 6, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Neoadjuvant Chemotherapy Improves Clinical Response in Breast Cancer
For premenopausal breast cancer patients, 24 weeks of neoadjuvant chemotherapy may yield a better clinical response than endocrine therapy. (Source: CancerNetwork)
Source: CancerNetwork - June 12, 2017 Category: Cancer & Oncology Authors: Mark Fuerst Tags: Conferences/ASCO Breast Cancer News Source Type: news

Palbociclib Might Reverse Acquired Breast Cancer Endocrine Resistance
Palbociclib alone and in combination with endocrine therapy offers clinical benefit among women with HR-positive, HER2-negative metastatic breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Breast Cancer News Source Type: news

Daily Texting Effectively Monitors Rx Adherence, Side Effects
Most patients with breast cancer taking endocrine therapy report intervention helpful in taking drugs (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 30, 2017 Category: Cancer & Oncology Tags: Gynecology, Nursing, Oncology, Pharmacy, Journal, Source Type: news

Predicting Response of Endocrine Therapy for Breast Cancer Predicting Response of Endocrine Therapy for Breast Cancer
Biomarkers, gene expression microarrays, circulating tumor cells, and circulating tumor DNA can help guide management of ER positive breast cancer.Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 13, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Prognostic Tests for Prediction of Breast Cancer Recurrence Prognostic Tests for Prediction of Breast Cancer Recurrence
Which prognostic assay best predicts which patients may need adjuvant chemotherapy after endocrine therapy?Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 20, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Soy Tied To Longer Life After Breast Cancer
(Reuters Health) - - Eating more soy may be tied to better survival odds for many women with breast cancer and may not be harmful for patients treated with hormones, a new study suggests. Previous nutrition research has linked soy to a longer life, but prior studies have also suggested soy may help tumors spread by making hormone-based cancer treatments, or endocrine therapy, less effective. For the current study, researchers examined data on 6,235 U.S. and Canadian women with breast cancer. More than half of the women were followed for at least nine years. During the course of the study, women who ate the most foods conta...
Source: Healthy Living - The Huffington Post - March 7, 2017 Category: Consumer Health News Source Type: news

Adding a Statin to Endocrine Therapy Tied to Improved Breast Cancer Outcomes Adding a Statin to Endocrine Therapy Tied to Improved Breast Cancer Outcomes
Starting cholesterol-lowering therapy with adjuvant endocrine therapy was associated with clinical outcome for patients with ER-positive breast cancer in the BIG 1-98 clinical trial, researchers have found.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 14, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Disparities in Adjuvant Endocrine Therapy for Breast Cancer Identified Disparities in Adjuvant Endocrine Therapy for Breast Cancer Identified
In the U.S, minorities and women under 40 and over 80 frequently don't receive adjuvant endocrine therapy (AET) for breast cancer, putting their lives at risk, researchers say. (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - February 9, 2017 Category: Surgery Tags: Diabetes & Endocrinology News Source Type: news

Uneven Use of Hormone Therapy in Breast Cancer (CME/CE)
(MedPage Today) -- Significant variations in care for adjuvant endocrine therapy (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - February 2, 2017 Category: Endocrinology Source Type: news

Under and misuse of hormone therapy decreasing, but still high
(University of Chicago Medical Center) A nationwide cancer registry of almost one million patients treated for hormone-sensitive breast cancer shows that one out of six women who should have received post-surgical treatment known as adjuvant endocrine therapy did not get this recommended component of care, which can reduce the odds of recurrence. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 2, 2017 Category: Cancer & Oncology Source Type: news

FALCON Breast Cancer Trial: Who's Naive Here? FALCON Breast Cancer Trial: Who's Naive Here?
In the FALCON trial, fulvestrant improved PFS in ER+ metastatic breast cancer patients who were endocrine-therapy naive, but the trial failed to answer key clinical questions, says Dr Lidia Schapira.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 6, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology Viewpoint Source Type: news

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
This research has been highlighted as a practice changing update by DynaMed Plus. It concludes that Fulvestrant has superior efficacy and is a preferred treatment option for patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not received previous endocrine therapy compared with a third-generation aromatase inhibitor, a standard of care for first-line treatment of these patients (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 4, 2017 Category: Consumer Health News Source Type: news

Stretching PFS in ER-Positive Metastatic Breast Cancer Stretching PFS in ER-Positive Metastatic Breast Cancer
In metastatic breast cancer, the current 14-16 months of PFS with endocrine therapy can be stretched to more than 20 months in the first-line setting, as explained in a plenary session at SABCS.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 21, 2016 Category: Consumer Health News Tags: Hematology-Oncology Article Source Type: news

Endocrine Therapy in Breast Cancer: Best Bet on Duration Endocrine Therapy in Breast Cancer: Best Bet on Duration
Dr Harold Burstein reviews the latest data on duration of adjuvant endocrine therapy in metastatic breast cancer, and provides much-needed recommendations on how to approach the topic with patients.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 19, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

One in Five Breast Cancer Patients Nonadherent to Endocrine Therapy
A study found that about 20% of women with breast cancer did not complete their prescribed endocrine therapy. (Source: CancerNetwork)
Source: CancerNetwork - December 16, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Breast Cancer News Source Type: news

Breast cancer patients fail to complete tamoxifen therapy
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, such as tamoxifen, according to researchers. (Source: Nursing Times)
Source: Nursing Times - December 14, 2016 Category: Nursing Source Type: news

Almost 20 percent of breast cancer patients fail to complete prescribed endocrine therapy
(European Society for Medical Oncology) Around 20 percent of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore. The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy were less likely to adhere to their medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 14, 2016 Category: Cancer & Oncology Source Type: news

B-52 Study: Estrogen Deprivation Bombs for Breast Ca (CME/CE)
(MedPage Today) -- Endocrine therapy fails to improve pre-surgery complete response rates (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - December 9, 2016 Category: Journals (General) Source Type: news

Precision Endocrine Therapy Possible in Breast Cancer Patients?
In a potential step toward precision endocrine therapy, a new study found that certain single nucleotide polymorphisms within CSMD1 are associated with changes in estrogen levels in postmenopausal breast cancer patients. (Source: CancerNetwork)
Source: CancerNetwork - December 9, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: News Conferences/SABCS 2016 Source Type: news

Ribociclib Increases Survival in HR+ Advanced Breast Cancer, But … Ribociclib Increases Survival in HR+ Advanced Breast Cancer, But …
Ribociclib + letrozole improves PFS in HR+ breast cancer, but Dr Lidia Schapira says more data are needed to identify which patients should receive endocrine therapy alone or combination therapy.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 9, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology Viewpoint Source Type: news

PI3K Inhibitor Delays Progression in Advanced HR-Positive Breast Cancer
Treatment with buparlisib in combination with endocrine therapy significantly improved PFS compared with placebo in patients with HR-positive advanced breast cancer that had progressed after treatment with everolimus plus exemestane. (Source: CancerNetwork)
Source: CancerNetwork - December 8, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: News Conferences/SABCS 2016 Source Type: news

Extending Adjuvant Endocrine Therapy: 3 Trials, Few Answers Extending Adjuvant Endocrine Therapy: 3 Trials, Few Answers
NSABP B-42, IDEAL and DATA trials dig down to small details.Medscape Medical News (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - December 7, 2016 Category: Radiology Tags: Hematology-Oncology News Source Type: news

Hormone therapy better than chemo before breast cancer surgery, study says
Doug G. WareBOSTON, Nov. 9 (UPI) -- Pre-surgery endocrine therapy for women with breast cancer might be every bit as good as chemotherapy, or even better, prominent new research said Wednesday. (Source: Health News - UPI.com)
Source: Health News - UPI.com - November 9, 2016 Category: Consumer Health News Source Type: news

Presurgical endocrine therapy less toxic than chemotherapy for ER-positive breast cancer
(Massachusetts General Hospital) Neoadjuvant endocrine therapy -- designed to reduce the size of breast tumors before surgical removal -- appears to be as effective as neoadjuvant chemotherapy for patients with localized, estrogen-receptor (ER)-positive breast cancer with considerably fewer side effects. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 9, 2016 Category: Cancer & Oncology Source Type: news

Adjuvant Endocrine Therapy Linked to Reduced Risk for Contralateral Breast Cancer in Community Setting (FREE)
By Amy Orciari Herman Edited by Andr é Sofair, MD, MPH, and William E. Chavey, MD, MS Findings from a real-world analysis, reported in JAMA Oncology, confirm that adjuvant endocrine therapy lowers the risk for contralateral breast cancer in … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - October 6, 2016 Category: Primary Care Source Type: news

Ibrance (palbociclib) for the Treatment of Metastatic Breast Cancer
Ibrance (palbociclib) is an oral formulation developed by Pfizer for the treatment of metastatic breast cancer in women with disease progression post endocrine therapy. (Source: Drug Development Technology)
Source: Drug Development Technology - September 29, 2016 Category: Pharmaceuticals Source Type: news

Compound Shows Promise as Next-Generation Prostate Cancer Therapy
Contact: Sarah Avery Phone: 919-660-1306 Email:sarah.avery@duke.eduhttps://www.dukehealth.orgEMBARGOED FOR RELEASE until 11 a.m. (ET) Monday, Aug. 8, 2016DURHAM, N.C. -- In the search for new ways to attack recurrent prostate cancer, researchers at Duke Health report that a novel compound appears to have a unique way of blocking testosterone from fueling the tumors in mice.The potential foundation for a next-generation therapy, called tetraaryl cyclobutane, or CB, is being studied as an option for prostate tumors that have grown resistant to current anti-androgen drugs, notably enzalutamide.“Prostate cancer is the mo...
Source: DukeHealth.org: Duke Health Features - August 8, 2016 Category: Pediatrics Tags: Duke Medicine Source Type: news

Adjuvant Endocrine Therapy for ER-Positive Breast Cancer Adjuvant Endocrine Therapy for ER-Positive Breast Cancer
When should premenopausal women with ER-positive breast cancer receive standard adjuvant therapy plus adjuvant ovarian suppression? Read the latest guideline update here.Journal of Clinical Oncology (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - August 8, 2016 Category: Pathology Tags: Hematology-Oncology Journal Article Source Type: news

Neoadjuvant Endocrine Therapy Can Be Helpful in Breast CancerNeoadjuvant Endocrine Therapy Can Be Helpful in Breast Cancer
In women with localized estrogen receptor-positive breast cancer, neoadjuvant endocrine therapy - even as monotherapy - prompts response rates similar to those of combination chemotherapy but with lower toxicity, according to a meta-analysis by U.S. researchers. Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - July 7, 2016 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Neoadjuvant endocrine therapy ‘a reasonable option’ for ER-positive breast cancer
Endocrine therapy should be reconsidered as a potential option in the neoadjuvant setting for localised oestrogen receptor-positive breast cancer, say the authors of a meta-analysis. (Source: MedWire News)
Source: MedWire News - July 1, 2016 Category: Consumer Health News Tags: Breast cancer Source Type: news

Factors affecting non-adherence to endocrine therapy
Publishing in the Journal of Asolescent and Young Adult Oncology, investigators conclude that tackling non-adherence in young women with breast cancer may come down to understanding and altering the way these patients perceive their treatment. Clinical Oncology (Source: Society for Endocrinology)
Source: Society for Endocrinology - June 3, 2016 Category: Endocrinology Source Type: news

Could statins prevent breast cancer returning?
Conclusion The study aimed to identify biological pathways that could be the reason why some ER+ breast cancers relapse after oestrogen-blocking treatment. It seems that one of the answers for treatment resistance lies in increased activity of cholesterol-producing pathways in the absence of oestrogen. The cholesterol molecules mimic oestrogen and stimulate further tumour growth. The researchers hope that their research could potentially highlight a new pathway, which could be used as a target for therapeutic treatment in the future. Dr Lesley-Ann Martin from the research team told the media, "This is hugely significa...
Source: NHS News Feed - June 2, 2016 Category: Consumer Health News Tags: Cancer Medication Source Type: news

ASCO's New Guideline for Endocrine Therapy in Breast CancerASCO's New Guideline for Endocrine Therapy in Breast Cancer
ASCO has a new guideline for the use of endocrine therapy in patients with hormone-receptor-positive metastatic breast cancer. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 1, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Widely used class of chemotherapy drugs does not lead to cognitive decline for women with breast cancer
UCLA Jonsson Comprehensive Cancer Center Dr. Patricia Ganz UCLA researchers have found that a commonly used chemotherapy drug does not appear to cause cognitive decline following treatment in women with breast cancer. The study, published online today in JAMA Oncology, refutes concerns raised by research published in 2015 in the same journal. The earlier study, which focused on a small group of women, suggested that a class of drugs called anthracyclines might increase the risk for attention, perception and mood deficits, and other neuropsychological issues, as well as cognitive difficulties, such as memory loss. Anthracy...
Source: UCLA Newsroom: Health Sciences - April 22, 2016 Category: Universities & Medical Training Source Type: news

Adjuvant endocrine therapy for premenopausal breast cancer patients should be individualized
Oncologists should take an individualized approach when making decisions about adjuvant endocrine therapies for premenopausal hormone receptor–positive, HER2-negative early breast cancer, suggests an... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - April 4, 2016 Category: Endocrinology Source Type: news

Neoadjuvant Endocrine Therapy Underused for Breast CancerNeoadjuvant Endocrine Therapy Underused for Breast Cancer
It does not work as fast as chemotherapy, but endocrine therapy increases breast conservation by downstaging disease. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 4, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Oncotype DX Testing Lets Some Breast Ca Patients Skip Chemo (CME/CE)
(MedPage Today) -- Low 21-gene score meant 98% disease-free survival with endocrine therapy alone (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 3, 2016 Category: Hematology Source Type: news

FDA expands Ibrance approval for metastatic breast cancer
Palbociclib (Ibrance, Pfizer), a cyclin-dependent kinase 4/6 inhibitor, is approved for use in combination with fulvestrant for the treatment of women with hormone receptor-positive, HER-2–negative metastatic breast cancer who progressed on endocrine therapy. Healio (Source: Society for Endocrinology)
Source: Society for Endocrinology - February 23, 2016 Category: Endocrinology Source Type: news

What factors affect non-compliance with endocrine therapy among young women with breast cancer?
A new study of young women with hormone receptor-positive breast cancer showed that more than half did not believe endocrine therapy was essential. Research was completed at Harvard Medical School. EurekAlert (Source: Society for Endocrinology)
Source: Society for Endocrinology - February 18, 2016 Category: Endocrinology Source Type: news